Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
HOME > ORGANIZATION
ORGANIZATION
- 19 Companies Join JPMA Task Force on Quality Evaluation of Nucleic Acid Therapeutics
September 18, 2018
- Think Tank Led by Ex-Pfizer Japan Chief to Compile Proposal on “100-Year Life” by Year-End
September 5, 2018
- Bayer Yakuhin Chief Prinz Named Vice Chairman of EFPIA Japan
September 3, 2018
- Ex-Pfizer Japan Chief Umeda to Now Helm Advocacy Group
August 29, 2018
- Over Half of Companies Control Supply of Off-Label Information: Ihoken Survey
August 27, 2018
- Regulatory Science Society Says “No” to Off-Label Info Supply by Drug Reps Conditionally OK’ed in Draft MHLW GLs
August 24, 2018
- Drug Wholesalers Post Virtually Flat Sales in FY2017: JPWA
August 10, 2018
- Total No. of Sales Reps Shrinks for 4 Years in a Row at 62,433: Survey
July 27, 2018
- Generic Use Rate at 74.1% in January-March: JGA
July 4, 2018
- Yokokura Wins 4th Term to Lead Japan Medical Association
June 25, 2018
- Expand Exemption Criteria in New Off-Patent Price Cut Rule: Japan Pharma Lobby
June 19, 2018
- Japan Pharma Group Calls for Careful Approach on PMP Deduction for Comparator Drugs
June 19, 2018
- Don’t Make Coverage Decision on CEA, Tweak Prices with Limited Scope: FPMAJ
June 18, 2018
- Scrap Unfair Company Criteria for Price Maintenance Premium: Japan Trade Group
June 18, 2018
- FPMAJ Welcomes Chuikyo’s Openness to Views of Experts on CEA: Drug Pricing Committee Chair
June 18, 2018
- Atsushi Kamide of Astellas Elected as New Chairman of FPMAJ’s Drug Pricing Committee
June 18, 2018
- Hiroki Nakatani Named as New Board Chair for GHIT Fund
June 8, 2018
- JPMA Proposes Creation of Disease Registry to Employ Medical Data
June 5, 2018
- New JPMA Chief Calls for Scrapping PMP Company Criteria
June 1, 2018
- Sawai President Elected New Generic Industry Chief
May 30, 2018
ページ
With Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) hogging the headlines for its biggest-ever price tag in Japan, many continue to perceive high-price medicines as the main culprit of strained health finances, contending that they are driving up drug spending. But, is…
The workforce in the Japanese pharmaceutical sector is getting leaner and leaner, with the latest securities reports filed by 27 drug makers showing a 1.3% fall in their headcounts in FY2018, or 888 employees. The downtrend has been continuing since…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…